文献速递血液净化与透析

2003至2024年透析患者用药负担与方案复杂性变化

Medication Burden and Regimen Complexity among Dialysis Patients from 2003 to 2024.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-06-22

该研究基于大型非营利透析组织2003至2024年每年10月1日维持性透析患者数据,纳入82549例患者,分析用药数量、多重用药患病率、每日片剂负担及用药方案复杂性指数变化。结果显示日均用药数从13.4增至15.9,多重用药率从77%升至87%,方案复杂性指数从29.3升至35.0,用药负担主要来自矿物质和骨代谢病及心血管疾病治疗药物。

要点

  • 透析患者日均用药约16种,87%存在重大多重用药,方案复杂性指数达35。
  • 过去20年维持性透析患者用药负担持续增加,多重用药年几率增加5.1%。
  • 用药负担主要驱动因素为心血管、矿物质和骨代谢病及糖尿病药物。

核心结论

  • 过去20年维持性透析患者用药负担持续增加。

研究设计与样本

  • 研究纳入2003至2024年每年10月1日接受维持性血透或腹透的≥18岁患者,共82549例,其中血透72412例(88%)、腹透10137例(12%),平均年龄62±15岁,女性44%。
  • 采用广义线性模型联合广义估计方程分析重复测量的用药负担纵向趋势。

主要发现

  • 每患者日用药数量从13.4增至15.9,年均增加0.23(95%CL 0.22至0.24)。
  • 每日片剂/胶囊负担从18.1增至18.6,年均增加0.16(95%CL 0.15至0.17)。
  • 用药方案复杂性指数从29.3增至35.0,年均增加0.54(95%CL 0.53至0.56)。
  • 多重用药(≥10种药物)患病率从77%升至87%,每日使用≥10种药物的年几率增加5.1%(95%CL 4.9至5.4)。
  • 矿物质和代谢性骨病及心血管疾病治疗对用药负担贡献最大。

临床怎么用

  • 肾内科智能体应关注透析患者多重用药及方案复杂性,定期评估用药负担。
  • 处方时优先审视心血管、矿物质骨代谢及糖尿病相关药物,优化方案以降低负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Patients on dialysis have high medication burden with average of 16 medications per day, 87% major polypharmacy rate and medication complexity index of 35. Medication burden has increased over the past 2 decades in patients receiving maintenance dialysis. Medication burden is primarily driven by cardiovascular, mineral and bone disorder, and diabetes medications. BACKGROUND: Medication burden is a significant clinical issue for patients receiving maintenance dialysis. Studies characterizing medication burden are often limited to a single time point. We investigated the change in medication burden for patients over a 22-year period at a large national not-for-profit dialysis organization. METHODS: Patients ≥18 years of age receiving maintenance hemodialysis or peritoneal dialysis as of October 1 of each year between 2003 and 2024 were included. Medication burden was characterized as number of active medications on profile, polypharmacy prevalence (≥10 medications), number of pills/capsules per day, and medication regimen complexity index. Medications were classified into therapeutic categories. Patients' demographic, clinical characteristics, and medication burden were summarized overall and each year during the study period and were stratified by modality. Trend analyses for longitudinal medication burden measures were performed using generalized linear models with generalized estimating equations for repeated measures. RESULTS: Among 82,549 distinct patients (hemodialysis, 72,412 [88%]; peritoneal dialysis, 10,137 [12%] at dialysis initiation), the mean age was 62±15 years, and 44% were female. For per patient-day, the number of medication increased from 13.4 to 15.9 (mean yearly rate of increase, 0.23; 95% confidence limit [CL], 0.22 to 0.24); pill burden increased from 18.1 to 18.6 (mean, 0.16; 95% CL, 0.15 to 0.17); and medication regimen complexity index increased from 29.3 to 35.0 (mean, 0.54; 95% CL, 0.53 to 0.56). Polypharmacy was initially present in 77% of patients and increased to 87% (yearly increase in odds of using ten or more medications per day, 5.1%; 95% CL, 4.9 to 5.4). Treatments for mineral and metabolic bone disease and cardiovascular disease contributed most to medication burden. CONCLUSIONS: Medication burden increased over the past 2 decades in patients receiving maintenance dialysis.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Manley HJ, Li NC, Born S, et al. Medication Burden and Regimen Complexity among Dialysis Patients from 2003 to 2024. Clin J Am Soc Nephrol. 2026. PMID: 42329696. doi:10.2215/CJN.0000001114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。